Compare · CBOE vs PPH
CBOE vs PPH
Side-by-side comparison of Cboe Global Markets, Inc. (CBOE) and VanEck Vectors Pharmaceutical ETF (PPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CBOE and PPH operate in n/a (n/a), so they compete in similar markets.
- CBOE carries a market cap of $13.01B.
- Over the past year, CBOE is up 43.0% and PPH is up 14.6% - CBOE leads by 28.4 points.
- CBOE has hit the wire 3 times in the past 4 weeks while PPH has been quiet.
- CBOE has more recent analyst coverage (25 ratings vs 0 for PPH).
Cboe Global Markets, Inc.
Cboe Global Markets, Inc., through its subsidiaries, operates as an options exchange worldwide. It operates through five segments: Options, North American Equities, Futures, European Equities, and Global FX. The Options segment trades in listed market indices. The North American Equities segment trades in listed U.S. and Canadian equities; and offers exchange-traded products (ETP) transaction and ETP listing services. The Futures segment trades in futures. The European Equities segment offers pan-European listed equities transaction services, ETPs, exchange-traded commodities, and international depository receipts, as well as ETP listings and clearing services. The Global FX segment provides institutional foreign exchange (FX) trading and non-deliverable forward FX transactions services. The company has strategic relationships with S&P Dow Jones Indices, LLC; FTSE International Limited; Frank Russell Company; MSCI Inc.; and DJI Opco, LLC. The company was formerly known as CBOE Holdings, Inc. and changed its name to Cboe Global Markets, Inc. in October 2017. Cboe Global Markets, Inc. was founded in 1973 and is headquartered in Chicago, Illinois.
VanEck Vectors Pharmaceutical ETF
The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
Latest CBOE
- Cboe Announces Agreement to Sell Cboe Australia and Cboe Canada to TMX Group
- Keefe Bruyette resumed coverage on Cboe Global Markets with a new price target
- Cboe Global Markets Reports Trading Volume for March 2026
- SEC Form DEF 14A filed by Cboe Global Markets, Inc.
- Cboe and CNBC Launch Multi-Year Collaboration to Deliver Daily Live Market Coverage from Chicago Trading Floor
- Amendment: SEC Form SCHEDULE 13G/A filed by Cboe Global Markets, Inc.
- Cboe Global Markets Announces Date of First-Quarter 2026 Earnings Release and Conference Call
- Cboe Files Proposal with the SEC to Launch Near 24x5 U.S. Equities Trading
- SEC Form 3 filed by new insider Johnston Scott L
- Cboe to Launch BITVX, A New Volatility Index Based on IBIT Options
Latest PPH
- VanEck Announces Year-End Distributions for VanEck Equity ETFs
- Ozempic Maker Novo Nordisk Closes In On Lego As Denmark's Most Valuable Brand: Report
- Novo Nordisk's Game-Changer: FDA Approves Weight Loss Sensation Wegovy For Heart Health, Potential Insurance Coverage
- 11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields
- Biden-Harris Administration Moves Forward with Medicare Drug Price Negotiations to Lower Prescription Drug Costs for People with Medicare